Use of monoclonal antibodies as a therapeutic option for breast cancer treatment: A review
Article Sidebar
Main Article Content
Abstract
[Objective] The objective of the research was to compile/analyze the information available about the use of monoclonal antibodies as a therapy for breast cancer. [Methodology] A bibliographic review was conducted using databases and journal publications addressing monoclonal antibodies as a treatment for cancer. The review focused on current data reflecting the scope and limitations of monoclonal therapy in different types of cancer. Additionally, a strategy was proposed to mitigate the negative side effects associated with the treatment in patients of cancer. [Results] Hybridoma cells target receptors responsible for the proliferation of cancer cells, such as HER2 in breast cancer, inhibiting their multiplication and facilitating the immune system’s ability to attack damaged cells through lymphocytes. Despite being a promising treatment, it has associated negative side effects. Therefore, an immunosuppression treatment plan is proposed to counteract these effects without compromising the therapy’s effectiveness. In Costa Rica, research including monoclonal antibodies as a potential cancer treatment should be promoted to improve patients’ quality of life. [Conclusions] The use of monoclonal antibodies as a treatment for breast cancer has shown positive results in patients, as it is a highly specific technique. However, many obstacles remain in its application, creating gaps that hinder research aimed at improving patient prognosis.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores conservan los derechos de autor y ceden a la revista el derecho de la primera publicación y pueda editarlo, reproducirlo, distribuirlo, exhibirlo y comunicarlo en el país y en el extranjero mediante medios impresos y electrónicos. Asimismo, asumen el compromiso sobre cualquier litigio o reclamación relacionada con derechos de propiedad intelectual, exonerando de responsabilidad a la Editorial Tecnológica de Costa Rica. Además, se establece que los autores pueden realizar otros acuerdos contractuales independientes y adicionales para la distribución no exclusiva de la versión del artículo publicado en esta revista (p. ej., incluirlo en un repositorio institucional o publicarlo en un libro) siempre que indiquen claramente que el trabajo se publicó por primera vez en esta revista.
References
V. Bayer, “An Overview of Monoclonal Antibodies,” Seminars in Oncology Nursing, vol. 35, no. 5, p. 150927, Oct. 2019, doi: https://doi.org/10.1016/j.soncn.2019.08.006.
D. Zahavi and L. Weiner, “Monoclonal Antibodies in Cancer Therapy,” Antibodies, vol. 9, no. 3, p. 34, Jul. 2020, doi: https://doi.org/10.3390/antib9030034.
N. Harbeck et al., “Breast cancer,” Nature Reviews Disease Primers, vol. 5, no. 1, Sep. 2019, doi: https://doi.org/10.1038/s41572-019-0111-2.
A. Astorga-Ramírez, J. Sánchez-Portuguez, and S. M. Solís-Barquero, “Revisión de los factores de riesgo y factores protectores para el cáncer de mama,” vol. 64, no. 4, pp. 1–11, Dec. 2022, doi: https://doi.org/10.51481/amc.v64i4.1177.
A. Barquero-Solano, G. Guevara-Saborío, J. Montero-Rivera, L. Vargas-Sandoval, L. D. Velásquez-Alfaro, and J. J. Mora-Román, “Inmunoterapia activa con anticuerpos monoclonales como opción terapéutica para el tratamiento del cáncer de páncreas,” Revista Tecnología en Marcha, Jun. 2022, doi: https://doi.org/10.18845/tm.v35i3.5612.
A. Waller-Pulido et al., “Production of monoclonal antibodies for therapeutic purposes: A review,” International Immunopharmacology, vol. 120, pp. 110376–110376, Jul. 2023, doi: https://doi.org/10.1016/j.intimp.2023.110376.
P. A. Jones and S. B. Baylin, “The Epigenomics of Cancer,” Cell, vol. 128, no. 4, pp. 683–692, Feb. 2007, doi: https://doi.org/10.1016/j.cell.2007.01.029.
S. M. Borgan, L. Romeus, S. Rahman, and A. Asmar, “Internal Medicine Residents and the Practice of Defensive Medicine: A Pilot Study Across Three Internal Medicine Residency Programs,” Cureus, Feb. 2020, doi: https://doi.org/10.7759/cureus.6876.
A. Samuel-Eziokwu et al., “Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer,” Clinical Breast Cancer, vol. 21, no. 3, pp. 205–209, Jun. 2021, doi: https://doi.org/10.1016/j.clbc.2020.09.010.
E. Quaquarini et al., “Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas,” Cancers, vol. 16, no. 18, pp. 3145–3145, Sep. 2024, doi: https://doi.org/10.3390/cancers16183145.
Z. Li, G. Xue, and Y. Mei, “Applications of Electrochemical Analytical Techniques in HER2 Detection for Breast Cancer,” International Journal of Electrochemical Science, pp. 100813–100813, Sep. 2024, doi: https://doi.org/10.1016/j.ijoes.2024.100813.
R. Ladak, B.A. Fifield, L. Porter, K. Hirmiz, and C. Hamm, “Long-Term Survival in Human Epidermal Growth Factor Receptor 2-Positive Bone-Only Metastatic Breast Cancer: Trastuzumab, Denosumab, and Potential Synergistic Effects,” Cureus, Sep. 2024, doi: https://doi.org/10.7759/cureus.68576.
T. Dajsakdipon, W. Pipatsakulroj, and T. Dejthevaporn, “Incidence and Prognostic Values in Human Epidermal Growth Factor Receptor 2-Low Expression Metastatic Breast Cancer in Southeast Asian Population: A 10-Year Retrospective Study,” JCO Global Oncology, no. 10, Sep. 2024, doi: https://doi.org/10.1200/go.24.00132.
V. Sankarapandian et al., “A review on tyrosine kinase inhibitors for targeted breast cancer therapy,” Pathology - Research and Practice, vol. 263, pp. 155607–155607, Sep. 2024, doi: https://doi.org/10.1016/j.prp.2024.155607.
H. Yun, L. Jing, J. Zhou, Y. Liu, and J. Zhang, “Poncirin Impact on Human HER2 Breast Cancer Cells: Inhibiting Proliferation, Metastasis, and Tumor Growth in Mice Potentially through The PI3K/AKT Pathway.,” PubMed, vol. 26, no. 8, pp. 496–504, Oct. 2024, doi: https://doi.org/10.22074/cellj.2024.2014892.1441.
D. G. Hicks and B. M. Turner, “Optimized biomarker evaluation and molecular testing in the era of breast cancer precision medicine,” Biotechnic & Histochemistry, pp. 1–13, Sep. 2024, doi: https://doi.org/10.1080/10520295.2024.2390179.
S. M. Lee, B. S. Jang, J. H. Chang, K. Kim, and K. H. Shin, “Risk Factors of Radiation Pneumonitis in Breast Cancer with Internal Mammary Chain Irradiation,” International Journal of Radiation Oncology*Biology*Physics, vol. 120, no. 2, p. e319, Oct. 2024, doi: https://doi.org/10.1016/j.ijrobp.2024.07.704.
J. Sánchez de Cos Escuín, “New Immunotherapy and Lung Cancer,” Archivos De Bronconeumologia, vol. 53, no. 12, pp. 682–687, Dec. 2017, doi: https://doi.org/10.1016/j.arbres.2017.06.016.
D. J. Slamon et al., “Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2,” New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, Mar. 2001, doi: https://doi.org/10.1056/nejm200103153441101.
D. Cunningham et al., “Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer,” New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, Jul. 2004, doi: https://doi.org/10.1056/nejmoa033025.
E. Herrero-García. “GRADO EN ENFERMERÍA Trabajo Fin de Grado,” 2019. Accessed: Nov. 19, 2024. [Online]. Disponible en: https://uvadoc.uva.es/bitstream/handle/10324/40652/TFG-L2570.pdf?sequence=1&isAllowed=y
M. D. Rombouts, E. L. Swart, A. J. M. van den Eertwegh, and M. Crul, “Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment,” Anticancer Research, vol. 40, no. 3, pp. 1201–1218, Mar. 2020, doi: https://doi.org/10.21873/anticanres.14062.
J. Q. Wei et al., “Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis,” Biomedicines, vol. 11, no. 7, pp. 1827–1827, Jun. 2023, doi: https://doi.org/10.3390/biomedicines11071827.
B. M. Bordeau and J. P. Balthasar, “Strategies to enhance monoclonal antibody uptake and distribution in solid tumors,” Cancer Biology and Medicine, vol. 18, no. 3, pp. 649–664, 2021, doi: https://doi.org/10.20892/j.issn.2095-3941.2020.0704.
A. Vaisman-Mentesh, M. Gutierrez-Gonzalez, B. J. DeKosky, and Y. Wine, “The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies,” Frontiers in Immunology, vol. 11, p. 1951, 2020, doi: https://doi.org/10.3389/fimmu.2020.01951.
A. Behl et al., “Monoclonal antibodies in breast cancer: A critical appraisal,” Critical Reviews in Oncology/Hematology, vol. 183, p. 103915, Mar. 2023, doi: https://doi.org/10.1016/j.critrevonc.2023.103915.
G. F. Bomfim, S. B. A. Cau, A. S. Bruno, A. G. Fedoce, and F. S. Carneiro, “Hypertension: a new treatment for an old disease? Targeting the immune system,” British Journal of Pharmacology, vol. 176, no. 12, pp. 2028–2048, Jul. 2018, doi: https://doi.org/10.1111/bph.14436.
A. O’Garra and P. Vieira, “Regulatory T cells and mechanisms of immune system control,” Nature Medicine, vol. 10, no. 8, pp. 801–805, Aug. 2004, doi: https://doi.org/10.1038/nm0804-801.
K. Bermúdez-Carvajal, G. H. Carrillo, R. M. Mata, K. R. Mora, B. Y.-A. Sánchez, and J. J. M. Román, “Anticuerpos monoclonales biespecíficos: desarrollo, producción y uso como terapia a anticancerígena,” Revista Médica de la Universidad de Costa Rica, vol. 13, no. 1, pp. 19–19, Apr. 2019, doi: https://doi.org/10.15517/rmucr.v13i1.37573.
A. San-Juan-Rodriguez, I. Hernandez, N. Parekh, and T. Newman, “Pricing of monoclonal antibodies in the United States,” Global Journal on Quality and Safety in Healthcare, vol. 1, no. 1, p. 4, 2018, doi: https://doi.org/10.4103/jqsh.jqsh_1_18.
Caja Costarricense del Seguro Social, “Caja Costarricense de Seguro Social | Lista oficial medicamentos,” Nov. 2024, Recuperado de: https://www.ccss.sa.cr/lom.